@article{38a5ce4d4e1e4a108b73d5b5a512aaf1,
title = "Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia",
abstract = "The diagnosis of primary plasma cell leukemia (pPCL) has been made by quantifying circulating plasma cells (cPCs) morphologically on a peripheral blood (PB) smear. However, this technique is not sufficiently sensitive. Multiparametric flow cytometry (MFC) provides a readily available and highly sensitive method to identify and quantify cPCs that could complement PB smear assessment. However, an optimal quantitative cutoff for cPCs by MFC to identify pPCL has not been established. Thus, a total of 591 patients newly diagnosed multiple myeloma (NDMM) patients who had their PB samples evaluated morphologically by PB smear, and immunophenotypically by MFC prior to beginning therapy were evaluated. The presence of ≥200 cPCs/μL by MFC (N = 25 or 5% of the total population) was chosen to identify patients with ≥5% cPCs by PB smear with a specificity of 99% and a sensitivity of 77%. For patients with ≥200 cPCs/μL by MFC compared to the remainder of the cohort, the median Time to next therapy (TTNT) was 18 vs 30 months and the median OS was 38 vs 70 months respectively. Thus, MFC assessment of PB can be utilized in conjunction with the morphological assessment of a PB smear to aid in improving the identification of pPCL among NDMM patients.",
author = "Evans, {Laura A.} and Dragan Jevremovic and Bharat Nandakumar and Angela Dispenzieri and Buadi, {Francis K.} and David Dingli and Lacy, {Martha Q.} and Hayman, {Suzanne R.} and Prashant Kapoor and Nelson Leung and Amie Fonder and Miriam Hobbs and Hwa, {Yi Lisa} and Eli Muchtar and Rahma Warsame and Kourelis, {Taxiarchis V.} and Ronald Go and Stephen Russell and Lust, {John A.} and Yi Lin and Mustaqeem Siddiqui and Kyle, {Robert A.} and Gertz, {Morie A.} and Rajkumar, {S. Vincent} and Kumar, {Shaji K.} and Gonsalves, {Wilson I.}",
note = "Funding Information: Research reported in this publication was supported by Mayo Clinic Hematological Malignancies Program and in part by grants from the National Cancer Institute of the National Institutes of Health under Award Numbers K23CA218742 and P50CA186781. It is also supported in part by the CTSA Grant UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Finally, this research is also supported in part by the Marion Schwartz Foundation for Multiple Myeloma. Funding Information: Research reported in this publication was supported by Mayo Clinic Hematological Malignancies Program and in part by grants from the National Cancer Institute of the National Institutes of Health under Award Numbers K23CA218742 and P50CA186781. It is also supported in part by the CTSA Grant UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Finally, this research is also supported in part by the Marion Schwartz Foundation for Multiple Myeloma. Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals, Inc.",
year = "2020",
month = jun,
day = "1",
doi = "10.1002/ajh.25773",
language = "English (US)",
volume = "95",
pages = "637--642",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "6",
}